Published in final edited form as:

Bioorg Med Chem. 2013 July 15; 21(14): 4051–4057. doi:10.1016/j.bmc.2012.11.023.

Plucking the High Hanging Fruit: A Systematic Approach for Targeting Protein-Protein Interactions

Monika Raj, Brooke N. Bullock, and Paramjit S. Arora

Department of Chemistry, New York University, New York, NY 10003, USA

Abstract

Development of specific ligands for protein targets that help decode the complexities of protein-protein interaction networks is a key goal for the field of chemical biology. Despite the emergence of powerful *in silico* and experimental high-throughput screening strategies, the discovery of synthetic ligands that selectively modulate protein-protein interactions remains a challenge for bioorganic and medicinal chemists. This Perspective discusses emerging principles for the rational design of PPI inhibitors. Fundamentally, the approach seeks to adapt nature's protein recognition principles for the design of suitable secondary structure mimetics.

Keywords

Protein-protein interactions; Secondary structure mimics; Computational design; Hot spot residues; Rational design

1. Introduction

Protein-protein interactions (PPIs) are attractive targets for therapeutic intervention because of their fundamental roles in vital biological processes including gene expression, cell growth, proliferation, nutrient uptake, morphology, motility, intercellular communication and apoptosis. The past decade has seen emerging methods to inhibit these complexes, which have traditionally been termed “undruggable”. Although it is early to say if inhibition of PPIs will become a routine strategy for drug design, preliminary success in the field provides guidelines for the types of interfaces that may be amenable to disruption by synthetic compounds.^{1–4} Pharmaceutical chemists often gravitate toward design of enzyme inhibitors as drug candidates – enzymes as a class constitute roughly half of drug targets.⁵ Enzymes are appealing targets for a list of reasons: (1) they serve as critical levers for biological functions, (2) nature offers small molecules that may be used as templates for further manipulation,⁶ (3) mechanism-based inhibitors may be rationally designed,⁷ and (4) enzyme pockets are often appropriately sized for small molecules.^{8, 9} The largely flat and pocket-less protein interfaces lack several of these features but are fascinating both because of basic challenges associated with molecular design and for the prospect of exploring relatively uncharted biology for therapeutic intervention.

© 2012 Elsevier Ltd. All rights reserved.

Corresponding author. arora@nyu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

2. A Secondary Structure-Centric View of Protein Interfaces

The Protein Data Bank, with roughly 10,000 entries of multiprotein complexes, provides a treasure of illustrations to unravel the rules nature employs to bring protein partners together (Figure 1). One approach for the design of synthetic inhibitors is based on rational design of protein subdomains to interfere with these complex formations.^{4, 10–13} A second successful method utilizes computational and experimental high-throughput and fragment-based screening strategies to locate small molecule fragments that stick to protein surfaces.^{14–19} Strategies that afford scaffolds for PPIs based on natural products and natural product like molecules,²⁰ peptide macrocycles²¹ and phage display-based miniproteins^{22–24} have also led to significant success. Although, PPIs cover large surface areas, often, a small subset of residues (termed “hot spot residues”) contributes significantly to the binding free energy.^{25–28} An analysis of PPIs, which have been successfully inhibited by small molecules, suggests that a category of PPIs contains features that approximate enzyme active sites, i.e., they contain an array of hot spot residues clustered within relatively small radii.^{27–29} With this viewpoint, we and others have assessed the dataset in the PDB³⁰ to identify the subset of PPIs that can be potential targets for small molecules, and those that would require larger molecules.^{4, 31–34} Several computational strategies to define *pockets* on protein-protein interfaces for drug design have been outlined.^{4, 35–39} Our approach has centered on the role of secondary structures in mediating protein-protein interactions.⁴⁰ A key advantage of designing protein secondary structure mimetics is that the array of side chain residues along a conformationally defined backbone facilitates molecular design. A second advantage is that direct mimics of protein secondary structures provide medium-sized molecules, which may potentially target the chosen protein with high affinity and specificity.

A basic challenge associated with this secondary structure-centric approach involves dissection of the energetic contribution of the specific secondary structure to the protein-protein complex. Three related questions include: (1) what is the minimum proportion of the free energy of binding that must reside on the secondary structure for its mimetic to retain inhibitory activity? (2) Are there interfaces that are naturally more suited for small mimics of target protein secondary structures and those that would require larger mimics? (3) How small can the mimetic be made to procure the “drug like” properties linked to small molecules while retaining specificity associated with larger molecules? We have undertaken computational efforts to probe these questions and have begun to experimentally evaluate hypotheses emerging from these studies.

Our initial analysis has focused on PPIs that feature helices at interfaces, although the approach can be extended to other motifs. Targeting of α -helical interfaces offers several basic advantages: α -helices constitute the largest class of protein secondary structures – roughly 60% of protein-protein interactions in the current PDB contain helices at interfaces.³¹ And, helices are often easier to mimic than other secondary structures such as β -strands, which tend to aggregate; although, there has been significant progress in the design of β -strand mimics.^{41–48} Importantly, stable mimics of interfacial helices have been shown to be useful as potential leads for drug design.^{11, 49–55}

In this Perspective, we discuss structural attributes of PPIs that our group uses to initiate design of either small molecule helix mimetics^{56–60} or stabilized peptide helices.^{10, 13, 61–63} Some interfaces may be targeted by either strategy. Stabilized peptide helices utilize constraints to order the peptide backbone while small molecule or nonpeptidic helix mimetics array the critical peptide side chain functional groups on a synthetic scaffold.¹³ On the basis of spatial arrangement of hotspot residues at the interface, revealed by alanine scanning mutagenesis data,^{64, 65} we classified PPIs as *binding clefts* or *extended interfaces*

(Figure 2).³¹ Receptors with clefts are targeted by helices with two or more hot spot residues within a 7 Å radius, while the extended interfaces category features a distribution of hot spot residues over a larger distance of 7–30 Å. Camacho and coworkers recently suggested that a combination of computed change in solvent accessible surface areas (Δ SASA) and energy scores may be a better gauge of hot spot residues than alanine scans alone.³³ For alanine mutagenesis scans, the $\Delta\Delta G$ value refers to the change in free energy when a residue is mutated to alanine, thus a positive value indicates that mutation to alanine decreases the affinity of PPI and wild type residue contributes to binding. For interfacial residues, the Δ SASA of a residue is calculated by subtracting the SASA of the residue in the PPI complex from the SASA of the individual residue without any partner protein chains, and a positive value indicates that the residue is buried in the PPI complex and less accessible to solvent. Rosetta^{29, 65} and PocketQuery⁶⁶ offer easily accessible resources for such computational analyses.

We hypothesized that a single turn of the α -helix approximates the distance traversed by typical small drug candidates,³⁹ i.e. Lipinski's "rules of five" compliant molecules.^{67, 68} Indeed, the classical small molecule inhibitors of PPIs – notably the nutlin family compounds developed by Roche to target the p53/Hdm2 complex – are mimics of residues that span one helical turn.^{69, 70} The high density of hot spot residues in *binding clefts* evoke array of functionality in enzymatic pockets. Based on this analysis, we postulate that *binding clefts* may be targetable by small molecule or nonpeptidic helix mimetics; however, *extended interfaces* that feature hot spot residues spanning a much larger number of helical turns will likely require medium to large sized molecules such as stabilized peptide helices for specific inhibition.³¹ Although, these larger inhibitors will not fit the mold of canonical "drug-like" molecules, emerging evidence suggests that macrocycles and other discretely folded molecules may translocate to target intracellular interactions.^{71–73}

We further classified interfacial interactions as potentially capable of leading to "high affinity" inhibitors if the average experimental/computed $\Delta\Delta G_{\text{avg}}$ for alanine mutagenesis of 2–4 hot spot residues is $\ll 2$ kcal/mol. These empirically derived values emerge from the analysis of known small molecule inhibitors of PPIs, as described previously.³¹ We predict that if the $\Delta\Delta G$ for alanine substitution of wild-type hot spot residues is $\ll 2$ kcal/mol, inhibitors based on wild-type sequence may bind the target protein with a low affinity (i.e. with dissociation constants in the micromolar range). However, this analysis only considers natural interactions and wild-type residues; use of non-natural residues may provide higher affinity leads. Furthermore, these predictions are based on high-resolution structures of multi-protein complexes and do not account for protein dynamics. Nevertheless, use of these rubrics has provided a starting point for the rational design of new classes of protein-protein interaction inhibitors.^{52, 74} Below, we discuss specific examples of protein complexes where the secondary structure-centric approach has been or could be applied to discover inhibitors.

3. Classification of helical protein interfaces

3.1. Binding Clefts

This category of PPIs contains a *cleft* for helical residues, that we predict are candidates for high throughput screening efforts with small molecule libraries;^{38, 75} medium-sized molecules such as stabilized peptide helices may also effectively modulate these interactions. Several members in this class of PPIs have been successfully targeted.^{3, 19} The reason for this success could be due to the fact that the physical attributes shared by members of this class are reminiscent of traditional enzyme targets.

The interaction of the p53 activation domain with MDM2 is perhaps the most successfully targeted protein-protein interaction.^{76–80} A number of inhibitors are currently in clinical

trials as potential cancer therapeutics.⁷⁶ The p53 AD adopts a helical conformation to target MDM2 with three hydrophobic hot spot residues on successive helical turns.⁶⁹ Successful synthetic analogs mimic two or all three of these residues.^{70, 77} The three hot spots lie close in space to each other with very large average alanine mutagenesis, $\Delta\Delta G_{\text{avg}} \sim 3.5$ kcal/mol, and ΔSASA values (Table 1). The interactions of Bcl-2 family anti-apoptotic proteins with the pro-apoptotic BH3 domains⁸¹ provide alanine scan and ΔSASA values of similarly high magnitude have also been successfully targeted with small molecules^{82–84} and stabilized helices.^{50, 85} Realization of potent inhibitors for these interactions suggests that complexes that feature a similar density of hot spot may also be targeted effectively. A full set of such complexes has been reported.³¹ Table 1 lists a few examples, with $\Delta\Delta G$ and ΔSASA values and relative positioning of hot spots, that fit our rubric for *cleft* interfaces.

3.2. Extended Helical Interfaces

Protein-protein interactions that involve discontinuous interaction surfaces with hot spot residues distributed over large contact areas are classified in this category. These PPIs are especially challenging for small molecule inhibitors but may be amenable to disruption by larger molecules such as stabilized helices and peptide foldamers. A full list of *extended helical interfaces* in the PDB has also been reported and select examples are shown in Table 1.³¹

The entry of HIV-1 into host cells requires formation of a coiled-coil bundle consisting of gp41 N-terminal and C-terminal helices.^{86–89} Design of small molecules that target this interaction with high affinity and specificity has been challenging;⁹⁰ however, potent inhibitors derived from peptide and β -peptide foldamers have been reported,^{53, 55, 91–94} in keeping with the broad distribution of hot spot residues at this interface.⁹⁵ Similarly, attempts to target the interaction of Ras and SOS with small molecules had been largely unsuccessful because two key residues on a Sos helix that contacts Ras are located four helical turns away from each other.^{96, 97} A stabilized helix that spans this length and encompasses key hot spot residues was recently developed as the first direct inhibitor of this complex formation,⁵² and regulator of the Ras signaling pathway.⁹⁸ Recent efforts in fragment screening suggest that small molecules that target an allosteric site on Ras may be designed to modulate activity of this therapeutically important target.^{99, 100}

4. Array of Hot Spots on Interfacial α -Helices

Based on the relative density of hot spots, the helical interfaces may be classified as *cleft* or *extended* as discussed above, allowing judicious design of inhibitors or screening strategies. As a next step, rational design of general classes of helix mimics as inhibitors requires mimicry of hot spot positioning on different helical faces. Examination of 480 interfacial helices with high alanine mutagenesis values, i.e. $\Delta\Delta G_{\text{avg}} \geq 2$ kcal/mol, provides an indication of the distribution of hot spots are arrayed on interfacial helices.³² Roughly 60% of helical interfaces in this dataset feature helices with hot spot residues on one face of the helix, a third of the complexes utilize helices with hot spots on two faces and roughly 10% require all three faces for interaction with the target protein partner.³² Examples of protein complexes with hot spot residues on one face, two faces and three faces are shown in Figure 3.

Several different synthetic strategies for helix mimicry have been reported.^{10, 11, 13} These include design of non-peptidic helix mimetics, constrained helices and foldamers that display protein-like functionality. Each of these strategies offers different advantages. The small molecules potentially excel at bioavailability, while the larger molecules offer additional contacts for enhanced specificity. Helical peptides and foldamers also provide ready access to scaffolds capable of displaying multiple hot spots on all three faces.³² We

hypothesize that interfaces that contain a cluster of hot spot residues on the same face of the helix are well suited for small molecules. There are >200 such complexes in the current PDB, providing an attractive opportunity for design of new therapeutics.

5. Conclusions

Mimicry of protein secondary structures has been a long-standing goal of bioorganic and medicinal chemists. Evaluation of protein complexes suggests that interfaces where the hot spot functionality is localized on secondary structures may be inhibited through rational design of peptidic and nonpeptidic scaffolds that feature key functional groups in the desired conformation. We have undertaken a comprehensive study to locate every helical protein-protein interaction in the Protein Data Bank. Computational analysis of these complexes allows prediction of interfaces that may be inhibited by small molecules because the hot spot residues are clustered in a small region or by larger molecules because the hot spots are distributed over a bigger area. We expect similar studies to facilitate future design of PPI inhibitors as new classes of therapeutics.

Acknowledgments

We thank the National Institutes of Health (GM073943) and the National Science Foundation (CHE-1151554) for financial support. B.N.B. thanks New York University for the Dean's Dissertation Fellowship.

References and notes

1. Morelli X, Bourgeas R, Roche P. *Curr Opin Chem Biol.* 2011; 15:475. [PubMed: 21684802]
2. Thangudu RR, Bryant SH, Panchenko AR, Madej T. *J Mol Biol.* 2012; 415:443. [PubMed: 22198293]
3. Wells JA, McClendon CL. *Nature.* 2007; 450:1001. [PubMed: 18075579]
4. Wanner J, Fry DC, Peng Z, Roberts J. *Future Med Chem.* 2011; 3:2021. [PubMed: 22098351]
5. Hopkins AL, Groom CR. *Nature reviews Drug discovery.* 2002; 1:727.
6. Drahl C, Cravatt BF, Sorensen EJ. *Angew Chem Int Ed.* 2005; 44:5788.
7. Babine RE, Bender SL. *Chemical reviews.* 1997; 97:1359. [PubMed: 11851455]
8. Laskowski RA, Luscombe NM, Swindells MB, Thornton JM. *Protein science : a publication of the Protein Society.* 1996; 5:2438. [PubMed: 8976552]
9. Dundas J, Adamian L, Liang J. *J Mol Biol.* 2011; 406:713. [PubMed: 21145898]
10. Garner J, Harding MM. *Organic & biomolecular chemistry.* 2007; 5:3577. [PubMed: 17971985]
11. Edwards TA, Wilson AJ. *Amino Acids.* 2011; 41:743. [PubMed: 21409387]
12. Goodman CM, Choi S, Shandler S, DeGrado WF. *Nat Chem Biol.* 2007; 3:252. [PubMed: 17438550]
13. Henchey LK, Jochim AL, Arora PS. *Curr Opin Chem Biol.* 2008; 12:692. [PubMed: 18793750]
14. Toogood PL. *J Med Chem.* 2002; 45:1543. [PubMed: 11931608]
15. Erlanson DA, Wells JA, Braisted AC. *Annu Rev Biophys Biomol Struct.* 2004; 33:199. [PubMed: 15139811]
16. Arkin MR, Wells JA. *Nature reviews Drug discovery.* 2004; 3:301.
17. Meireles LM, Mustata G. *Current topics in medicinal chemistry.* 2011; 11:248. [PubMed: 21320056]
18. Congreve M, Chessari G, Tisi D, Woodhead AJ. *J Med Chem.* 2008; 51:3661. [PubMed: 18457385]
19. Hajduk PJ, Greer J. *Nature reviews Drug discovery.* 2007; 6:211.
20. Tan DS. *Nat Chem Biol.* 2005; 1:74. [PubMed: 16408003]
21. Terrett NK. *Drug Discovery Today: Technologies.* 2010; 7:e97.

22. Herman RE, Badders D, Fuller M, Makienko EG, Houston ME, Quay SC, Johnson PH. *J Biol Chem*. 2007; 282:9813. [PubMed: 17264074]
23. Hu B, Gilkes DM, Chen J. *Cancer Research*. 2007; 67:8810. [PubMed: 17875722]
24. Gemperli AC, Rutledge SE, Maranda A, Schepartz A. *J Am Chem Soc*. 2005; 127:1596. [PubMed: 15700967]
25. Clackson T, Wells JA. *Science*. 1995; 267:383. [PubMed: 7529940]
26. Keskin O, Gursoy A, Ma B, Nussinov R. *Chemical reviews*. 2008; 108:1225. [PubMed: 18355092]
27. Bogan AA, Thorn KS. *J Mol Biol*. 1998; 280:1. [PubMed: 9653027]
28. Moreira IS, Fernandes PA, Ramos MJ. *Proteins*. 2007; 68:803. [PubMed: 17546660]
29. Kortemme T, Baker D. *Proc Natl Acad Sci USA*. 2002; 99:14116. [PubMed: 12381794]
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. *Nucleic Acids Res*. 2000; 28:235. [PubMed: 10592235]
31. Jochim AL, Arora PS. *ACS Chem Biol*. 2010; 5:919. [PubMed: 20712375]
32. Bullock BN, Jochim AL, Arora PS. *J Am Chem Soc*. 2011; 133:14220. [PubMed: 21846146]
33. Koes DR, Camacho CJ. *Bioinformatics*. 2012; 28:784. [PubMed: 22210869]
34. Bourgeas R, Basse MJ, Morelli X, Roche P. *PLoS One*. 2010; 5:e9598. [PubMed: 20231898]
35. Henrich S, Salo-Ahen OM, Huang B, Rippmann FF, Cruciani G, Wade RC. *Journal of molecular recognition : JMR*. 2010; 23:209. [PubMed: 19746440]
36. Reynes C, Host H, Camproux AC, Laconde G, Leroux F, Mazars A, Deprez B, Fahraeus R, Villoutreix BO, Sperandio O. *PLoS Comput Biol*. 2010; 6:e1000695. [PubMed: 20221258]
37. Nayal M, Honig B. *Proteins*. 2006; 63:892. [PubMed: 16477622]
38. Higuero AP, Schreyer A, Bickerton GR, Pitt WR, Groom CR, Blundell TL. *Chem Biol Drug Des*. 2009; 74:457. [PubMed: 19811506]
39. Davis FP, Sali A. *PLoS Comput Biol*. 2010; 6:e1000668. [PubMed: 20140189]
40. Jochim AL, Arora PS. *Mol Biosyst*. 2009; 5:924. [PubMed: 19668855]
41. Hammond MC, Harris BZ, Lim WA, Bartlett PA. *Chem Biol*. 2006; 13:1247. [PubMed: 17185220]
42. Khasanova TV, Khakshoor O, Nowick JS. *Org Lett*. 2008; 10:5293. [PubMed: 18937484]
43. Loughlin WA, Tyndall JDA, Glenn MP, Fairlie DP. *Chemical reviews*. 2004; 104:6085. [PubMed: 15584696]
44. Smith AB, Keenan TP, Holcomb RC, Sprengeler PA, Guzman MC, Wood JL, Carroll PJ, Hirschmann R. *J Am Chem Soc*. 1992; 114:10672.
45. Angelo NG, Arora PS. *J Am Chem Soc*. 2005; 127:17134. [PubMed: 16332031]
46. Angelo NG, Arora PS. *J Org Chem*. 2007; 72:7963. [PubMed: 17880241]
47. Ko E, Liu J, Burgess K. *Chemical Society reviews*. 2011; 40:4411. [PubMed: 21483946]
48. Ko E, Liu J, Perez LM, Lu G, Schaefer A, Burgess K. *J Am Chem Soc*. 2010; 133:462. [PubMed: 21182254]
49. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. *Nature*. 2009; 462:182. [PubMed: 19907488]
50. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ. *Science*. 2004; 305:1466. [PubMed: 15353804]
51. Stewart ML, Fire E, Keating AE, Walensky LD. *Nat Chem Biol*. 2010; 6:595. [PubMed: 20562877]
52. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. *Nat Chem Biol*. 2011; 7:585. [PubMed: 21765406]
53. Horne WS, Johnson LM, Ketas TJ, Klasse PJ, Lu M, Moore JP, Gellman SH. *Proc Natl Acad Sci USA*. 2009; 106:14751. [PubMed: 19706443]
54. Harrison RS, Shepherd NE, Hoang HN, Ruiz-Gomez G, Hill TA, Driver RW, Desai VS, Young PR, Abbenante G, Fairlie DP. *Proc Natl Acad Sci U S A*. 2010; 107:11686. [PubMed: 20543141]
55. Stephens OM, Kim S, Welch BD, Hodsdon ME, Kay MS, Schepartz A. *J Am Chem Soc*. 2005; 127:13126. [PubMed: 16173723]
56. Cummings CG, Hamilton AD. *Curr Opin Chem Biol*. 2010; 14:341. [PubMed: 20430687]

57. Tosovska P, Arora PS. *Org Lett*. 2010; 12:1588. [PubMed: 20196543]
58. Lee JH, Zhang Q, Jo S, Chai SC, Oh M, Im W, Lu H, Lim HS. *J Am Chem Soc*. 2011; 133:676. [PubMed: 21171592]
59. Plante JP, Burnley T, Malkova B, Webb ME, Warriner SL, Edwards TA, Wilson AJ. *Chem Commun*. 2009:5091.
60. Shaginian A, Whitby LR, Hong S, Hwang I, Farooqi B, Searcey M, Chen J, Vogt PK, Boger DL. *J Am Chem Soc*. 2009; 131:5564. [PubMed: 19334711]
61. Patgiri A, Jochim AL, Arora PS. *Acc Chem Res*. 2008; 41:1289. [PubMed: 18630933]
62. Schafmeister CE, Po J, Verdine GL. *J Am Chem Soc*. 2000; 122:5891.
63. Shepherd NE, Hoang HN, Abbenante G, Fairlie DP. *J Am Chem Soc*. 2005; 127:2974. [PubMed: 15740134]
64. Cunningham BC, Wells JA. *Science*. 1989; 244:1081. [PubMed: 2471267]
65. Kortemme T, Kim DE, Baker D. *Science's STKE : signal transduction knowledge environment*. 2004; 2004:pl2.
66. Koes DR, Camacho CJ. *Nucleic Acids Res*. 2012; 40:W387. [PubMed: 22523085]
67. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Advanced Drug Delivery Reviews*. 1997; 23:3.
68. Hann MM, Keseru GM. *Nature reviews Drug discovery*. 2012; 11:355.
69. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. *Science*. 1996; 274:948. [PubMed: 8875929]
70. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. *Science*. 2004; 303:844. [PubMed: 14704432]
71. Alex A, Millan DS, Perez M, Wakenhut F, Whitlock GA. *Medchemcomm*. 2011; 2:669.
72. White TR, Renzelman CM, Rand AC, Rezai T, McEwen CM, Gelev VM, Turner RA, Linington RG, Leung SSF, Kalgutkar AS, Bauman JN, Zhang Y, Liras S, Price DA, Mathiowetz AM, Jacobson MP, Lokey RS. *Nat Chem Biol*. 2011; 7:810. [PubMed: 21946276]
73. Arora PS, Ansari AZ. *Nature*. 2009; 462:171. [PubMed: 19907487]
74. Henchey LK, Kushal S, Dubey R, Chapman RN, Olenyuk BZ, Arora PS. *J Am Chem Soc*. 2010; 132:941. [PubMed: 20041650]
75. Welsch ME, Snyder SA, Stockwell BR. *Curr Opin Chem Biol*. 2010; 14:347. [PubMed: 20303320]
76. Cheok CF, Verma CS, Baselga J, Lane DP. *Nat Rev Clin Oncol*. 2011; 8:25. [PubMed: 20975744]
77. Shangary S, Wang S. *Annu Rev Pharmacol Toxicol*. 2009; 49:223. [PubMed: 18834305]
78. Vassilev LT. *Trends Mol Med*. 2007; 13:23. [PubMed: 17126603]
79. Chene P. *Nat Rev Cancer*. 2003; 3:102. [PubMed: 12563309]
80. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. *J Am Chem Soc*. 2007; 129:2456. [PubMed: 17284038]
81. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. *Science*. 1997; 275:983. [PubMed: 9020082]
82. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD. *Nat Chem Biol*. 2012; 8:639. [PubMed: 22634637]
83. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. *Nature*. 2005; 435:677. [PubMed: 15902208]
84. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. *Cell Death Differ*. 2008; 16:360. [PubMed: 18806758]
85. Stewart ML, Fire E, Keating AE, Walensky LD. *Nat Chem Biol*. 2010; 6:595. [PubMed: 20562877]
86. Eckert DM, Kim PS. *Annu Rev Biochem*. 2001; 70:777. [PubMed: 11395423]
87. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. *Nature*. 1997; 387:426. [PubMed: 9163431]

88. Tan K, Liu J, Wang J, Shen S, Lu M. *Proc Natl Acad Sci U S A*. 1997; 94:12303. [PubMed: 9356444]
89. Chan DC, Fass D, Berger JM, Kim PS. *Cell*. 1997; 89:263. [PubMed: 9108481]
90. Pan C, Liu S, Jiang S. *J Formos Med Assoc*. 2010; 109:94. [PubMed: 20206833]
91. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. *Nature reviews Drug discovery*. 2004; 3:215.
92. Wang D, Lu M, Arora PS. *Angew Chem Int Ed*. 2008; 47:1879.
93. Sia SK, Carr PA, Cochran AG, Malashkevich VN, Kim PS. *Proc Natl Acad Sci USA*. 2002; 99:14664. [PubMed: 12417739]
94. Ernst JT, Kutzki O, Debnath AK, Jiang S, Lu H, Hamilton AD. *Angew Chem Int Ed*. 2002; 41:278.
95. Johnson LM, Horne WS, Gellman SH. *J Am Chem Soc*. 2011; 133:10038. [PubMed: 21644542]
96. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J. *Nature*. 1998; 394:337. [PubMed: 9690470]
97. Hall BE, Yang SS, Boriack-Sjodin PA, Kuriyan J, Bar-Sagi D. *J Biol Chem*. 2001; 276:27629. [PubMed: 11333268]
98. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. *Nat Rev Cancer*. 2011; 11:761. [PubMed: 21993244]
99. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G. *Proc Natl Acad Sci USA*. 2012; 109:5299. [PubMed: 22431598]
100. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. *Angew Chem Int Ed*. 2012; 51:6140.
101. Henchey LK, Porter JR, Ghosh I, Arora PS. *ChemBiochem*. 2010; 11:2104. [PubMed: 20821791]
102. Kritzer JA, Lear JD, Hodsdon ME, Schepartz A. *J Am Chem Soc*. 2004; 126:9468. [PubMed: 15291512]
103. Murray JK, Gellman SH. *Biopolymers*. 2007; 88:657. [PubMed: 17427181]
104. Fasan R, Dias RLA, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA. *Angew Chem Int Ed*. 2004; 43:2109.
105. Yin H, Lee G-i, Park HS, Payne GA, Rodriguez JM, Sebt SM, Hamilton AD. *Angew Chem Int Ed*. 2005; 44:2704.
106. Austin RJ, Ja WW, Roberts RW. *J Mol Biol*. 2008; 377:1406. [PubMed: 18329041]
107. Millward SW, Fiacco S, Austin RJ, Roberts RW. *ACS Chem Biol*. 2007; 2:625. [PubMed: 17894440]
108. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW. *J Med Chem*. 2007; 50:641. [PubMed: 17256834]
109. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. *Cancer Res*. 2008; 68:3421. [PubMed: 18451170]
110. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. *Nat Cell Biol*. 2001; 3:173. [PubMed: 11175750]
111. Yang B, Liu D, Huang Z. *Bioorg Med Chem Lett*. 2004; 14:1403. [PubMed: 15006371]
112. Wang D, Liao W, Arora PS. *Angew Chem Int Ed*. 2005; 44:6525.
113. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. *J Am Chem Soc*. 2002; 124:11838. [PubMed: 12358513]
114. Lee J, Kim K-H, Jeong S. *Bioorganic & Medicinal Chemistry Letters*. 2011; 21:4203. [PubMed: 21684737]
115. Bramson HN, Corona J, Davis ST, Dickerson SH, Edelstein M, Frye SV, Gampe RT Jr, Harris PA, Hassell A, Holmes WD, Hunter RN, Lackey KE, Lovejoy B, Luzzio MJ, Montana V,

Rocque WJ, Rusnak D, Shewchuk L, Veal JM, Walker DH, Kuyper LF. J Med Chem. 2001; 44:4339. [PubMed: 11728181]

116. Frey G, Rits-Volloch S, Zhang XQ, Schooley RT, Chen B, Harrison SC. Proc Natl Acad Sci USA. 2006; 103:13938. [PubMed: 16963566]

117. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, Oprian D, Schreiber SL, Wiley DC, Harrison SC. Nat Struct Biol. 1999; 6:953. [PubMed: 10504731]

Figure 1. Protein-protein interactions are often mediated by secondary structures: (a) α -helical and (b) β -sheet interfaces from barnase_barstar (PDB code: 1BGS) and Raf-Rap (PDB code: 1GUA), respectively.

Figure 2.

Helical interfaces can be divided between those that feature *clefts* for binding and those with *extended interfaces*. The cleft interfaces may be compared to enzyme pockets in that a high density of important contacts is concentrated in a small region. The Gleevek/tyrosine kinase (PDB code: 1XBB), p53/MDM2 (PDB code: 1YCR) and cyclin- dependent kinase6/D-type viral cyclin (PDB code: 1G3N) complexes are representative examples of enzyme pockets, binding cleft and extended interfaces, respectively.

Figure 3.

(a) Positioning of side-chain residues on a canonical α -helix. (b–d) examples of protein complexes with hot spot residues on one face, two faces, and three faces. (b) Yersinia pestis YopN/TyeA complex, PDB code 1XL3; (c) ligand-binding domain (LBD) of the retinoid X receptor/coactivator complex (PDB code 1XIU); (d) E. coli sigma factor/anti-sigma RseA complex, PDB code 1OR7.

Table 1

Classification of helical protein interfaces.

Types of PPIs	PDB code, helix sequence	Arrangement of hot spot residues on the target helix	$\Delta\Delta G$ (kcal/mol) ¹	$\Delta SASA$ ²	Known Inhibitors	Protein names Function
Interfaces with Binding Clefts
1YCR 19TSDLWKLLPE ²⁸	i	3.8	131.1	1 Small molecules ^{70, 77} 2 Helix mimetics ^{59, 60, 80, 101–105}	MDM2 (gray): coactivator p53 (green): transcriptional activator. Function: Apoptotic signaling, cell-cycle arrest
		i + 4	4.4	136.7		
		i + 7	2.0	73.4		
		(Avg)	(3.4)	(113.7)
1Y3A 5WYDFLM ¹⁰	i	4.2	168.3	1 Linear peptide ¹⁰⁶ 2 Cyclic peptides ¹⁰⁷	Gta. 1 (gray): Guanine nucleotide-binding protein alpha-1 subunit KB752 (green): peptide Function: Signaling protein
		i + 3	3.3	93.9		
		i + 4	1.8	83.8		
		(Avg)	(3.1)	(115.3)
1BXL 578LAIIGDDI ⁵⁸⁵	i	2.7	102.2	1 Small molecules ^{82, 108–110} 2 Helix mimetics ^{50, 111–113}	BCL-XL (gray): BAK peptide (green): Function: apoptosis
		i + 3	2.2	87.3		
		i + 7	1.2	79.3		
		(Avg)	(2.0)	(89.6)
1JSU 85PEFYR ⁹⁰	i	2.9	122.1	1 Small molecules ^{114, 115}	CDK2(gray): cyclin dependent kinase-2 P27(KIP1): kinase inhibitor (blue, helix in green) Function: Enzyme Kinase
		i+1	4.9	116.8		
		i+3	1.1	64.6		
		(Avg)	(3.0)	(101.2)		

Types of PPIs	PDB code, helix sequence	Arrangement of hot spot residues on the target helix	$\Delta\Delta G$ (kcal/mol) ¹	$\Delta SASA$ ²	Known Inhibitors	Protein names Function
Extended Helical Interfaces
1A1K 62 ^{SW} MEWDREINNYTSLJ ⁶⁴²	i	2.8	160.69	1 Small molecules ^{116, 117} 2 Linear peptide ⁹¹ and helix mimetics ^{53, 55, 91-94}	HR1 (gray): N-terminal heptad repeat of HIV-1 GP41 HR2 (green): C-terminal heptad repeat of HIV-1 GP41 Function: glycoprotein
		i + 3	1.92	124.62		
		i + 10	2.01	77.32		
		i + 14	1.76	92.59
3BXX 196 ^{IY} AAMMIMEYYRQS1 ⁹⁷⁴	(Avg)	(2.12)	(113.8)	No known inhibitors	Ca2+-CaM (gray): calmodulin Cav 2.1 IQ (green): voltage gated calcium channels-Isoleucine-glutamine Function: Signaling protein
		i	1.9	130.49		
		i + 1	1.6	105.38		
		i + 4	1.0	104.8
1NVW 930 ^{FG} LYLTNLIKTEEGN ⁹⁴⁴	i + 6	3.1	111.97	1 Small molecule ^{99, 100} 2 Helix mimetics ⁵²	Ras (gray): guanine nucleotide binding protein Sos (blue, helix in green): Ras-specific guanine nucleotide exchange factor Function: signaling protein
		i + 10	2.7	103.28		
		i + 11	2.0	107.88		
		(Avg)	(2.05)	(110.6)
1K90 82 ^{EE} EIREAFRVFDK ⁹⁴	i	1.64	43.73	No known inhibitors	EF(gray): Edema factor Calmodulin (blue, helix in green): Function: Anthrax Toxin
		i + 6	1.11	57.75		
		i + 13	1.10	57.98		
		i + 15	2.35	67.70
1K90 82 ^{EE} EIREAFRVFDK ⁹⁴	(Avg)	(1.55)	(56.79)	No known inhibitors	EF(gray): Edema factor Calmodulin (blue, helix in green): Function: Anthrax Toxin
		i	0.71	78.71		
		i + 3	1.99	90.67		
		i + 6	1.84	105.7
1K90 82 ^{EE} EIREAFRVFDK ⁹⁴	i + 7	1.26	81.14	No known inhibitors	EF(gray): Edema factor Calmodulin (blue, helix in green): Function: Anthrax Toxin
		i + 10	1.53	64.99		
		(Avg)	(1.47)	(84.24)		

¹ Calculated using computational alanine scanning suite of Rosetta.⁶⁵

² Obtained from PocketQuery.^{33, 66} Numbers in parentheses refer to average of $\Delta\Delta G$ or $\Delta SASA$ values for hot spot residues.